A First-Generation Multi-Functional Cytokine for Simultaneous Optical Tracking and Tumor Therapy

DSpace/Manakin Repository

A First-Generation Multi-Functional Cytokine for Simultaneous Optical Tracking and Tumor Therapy

Citable link to this page

 

 
Title: A First-Generation Multi-Functional Cytokine for Simultaneous Optical Tracking and Tumor Therapy
Author: Hingtgen, Shawn; Kasmieh, Randa; Elbayly, Elizabeth; Nesterenko, Irina; Figueiredo, Jose-Luiz; Dash, Rupesh; Sarkar, Devanand; Kozakov, Dima; Vajda, Sandor; Fisher, Paul B.; Hall, David; Shah, Khalid A.

Note: Order does not necessarily reflect citation order of authors.

Citation: Hingtgen, Shawn, Randa Kasmieh, Elizabeth Elbayly, Irina Nesterenko, Jose-Luiz Figueiredo, Rupesh Dash, Devanand Sarkar, David Hall, Dima Kozakov, Sandor Vajda, Paul B. Fisher, and Khalid Shah. 2012. A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. PLoS ONE 7(7): e40234.
Full Text & Related Files:
Abstract: Creating new molecules that simultaneously enhance tumor cell killing and permit diagnostic tracking is vital to overcoming the limitations rendering current therapeutic regimens for terminal cancers ineffective. Accordingly, we investigated the efficacy of an innovative new multi-functional targeted anti-cancer molecule, SM7L, using models of the lethal brain tumor Glioblastoma multiforme (GBM). Designed using predictive computer modeling, SM7L incorporates the therapeutic activity of the promising anti-tumor cytokine MDA-7/IL-24, an enhanced secretory domain, and diagnostic domain for non-invasive tracking. In vitro assays revealed the diagnostic domain of SM7L produced robust photon emission, while the therapeutic domain showed marked anti-tumor efficacy and significant modulation of p38MAPK and ERK pathways. In vivo, the unique multi-functional nature of SM7L allowed simultaneous real-time monitoring of both SM7L delivery and anti-tumor efficacy. Utilizing engineered stem cells as novel delivery vehicles for SM7L therapy (SC-SM7L), we demonstrate that SC-SM7L significantly improved pharmacokinetics and attenuated progression of established peripheral and intracranial human GBM xenografts. Furthermore, SC-SM7L anti-tumor efficacy was augmented in vitro and in vivo by concurrent activation of caspase-mediated apoptosis induced by adjuvant SC-mediated S-TRAIL delivery. Collectively, these studies define a promising new approach to treating highly aggressive cancers, including GBM, using the optimized therapeutic molecule SM7L.
Published Version: doi:10.1371/journal.pone.0040234
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394792/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10456185
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters